Emisphere Technologies, Inc. Reports Update on the Clinical Development of Oral Calcitonin in Osteoarthritis and Osteoporosis

CEDAR KNOLLS, N.J., Dec. 14, 2011 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCQB:EMIS) ("Emisphere" or the "Company") announced today that Novartis Pharma AG ("Novartis") has informed the Company that it will not pursue further clinical development of the investigational drug SMC021 (oral calcitonin) being studied by Nordic Bioscience (the exclusive license partner of Novartis) as a treatment option in two indications, osteoarthritis (OA) and for post-menopausal osteoporosis (OP) and that it will not seek regulatory submission for SMC021 in OA or OP indications.